Chronic obstructive pulmonary disease (COPD) is the most common respiratory disease in the population of working age people and represents a very serious health problem in both developed and developing world.
INTRODUCTION

Summary
The prognosis of patients with chronic obstructive pulmonary disease is still uncertain, especially when the primary disease is further complicated with depression symptoms, the treatment of which represents a very complex therapeutic problem. Depression symptoms appear very often in patients suffering from chronic obstructive pulmonary disease, and the prevalence identified in different studies is from 16 % to 74 %. The variability in the study is caused by the different stages of the disease in which patients are found at the time of observation, assessment methods and the different diagnostic criteria for chronic obstructive pulmonary disease and depression. Chronic obstructive pulmonary disease is associated with numerous comorbidities, (including depression) and it is significant since it leads to more frequent use of health services, frequent hospitalizations and poor physical and social functioning. Patients suffering from chronic obstructive lung diseases are among the most accessible populations suitable for preventive work: they are the high-risk population and in constant contact with health professionals that can facilitate diagnosis and timely treatment of depression symptoms.
Key words: chronic obstructive pulmonary disease, prevalence, depression nary disease was said to be 7.6 %; COPD was reported to be higher in smokers and ex-smokers compared to non-smokers and noted to be prevalent in population over 40 years of age being present more in men than in women [4] . The BOLD study conducted in 12 world countries, both developed and developing ones, with 9425 respondents estimated10.1 % of prevalence of chronic obstructive pulmonary disease. In a study conducted in South America, the prevalence of chronic obstructive pulmonary disease was determined from 7.8 % to 20 % of cases [5] [6] .
According to the definition of the Global Strategy for the Diagnosis, treatment and prevalence of chronic obstructive pulmonary disease (GOLD) is characterized by airflow limitation which is not fully reversible, progressive and associated with an abnormal inflammatory lung response to harmful particles and gases. The airflow limitation is based on the inflammation occurring in the small airways and lung parenchyma. Chronic inflammation causes structural changes and narrowing of the small airways. The destruction of the parenchyma, occurring as a part of the inflammatory process, leads to the reduction of elasticity being followed by the destruction of the lung parenchyma and the development of emphysema [1, 2, 8] .
The clinical diagnosis of chronic obstructive pulmonary disease is based on characteristic symptoms such as the existence of dyspnea, chronic cough and sputum production, and history and spirometric examinations. Forced expiratory lung capacity (FEV1) is the most commonly used parameter in assessing the lung function damage. The ratio of FEV1 / FVC < 70 % indicates obstructive lung ventilation, while the assessment of the severity of obstructive disorders is based on the FEV 1 value [1] .
The assessment of severity of chronic obstructive pulmonary disease is performed on the basis of FEV1. In relation to the value of FEV1, there are mild, moderately severe, severe and very severe chronic obstructive pulmonary diseases. The value of FEV1 < 80 % characterizes mild chronic obstructive pulmonary disease, 50-80 % moderately severe, 30-50 % severe and < 30 % very severe chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease is often accompanied by depression symptoms. It is difficult to differentiate between depression and chronic obstructive pulmonary disease because their symptoms are intertwined. A large number of psychological and physical symptoms refer to both disorders: increased symptoms of fatigue, sleep disturbance, appetite, concentration difficulty, reduced mobility and deceleration [7] [8] . People with depression, smoke more frequently and more intensely, so it reflects negatively on the smoking cessation. Depression in patients with chronic obstructive pulmonary disease reduces the quality of life and reduces work capacity [9] . A regular monitoring of the quality of life is an important parameter in the clinical management of patients, because indicators such as lung function are of limited value. The research results show that the respiratory and physical symptoms are associated with depression in patients with chronic obstructive pulmonary disease while that is not the case with the factors such as age, sex, education, FEV1 and comorbidities [10] . FEV1 is accepted as a reliable indicator of physiological severity of chronic obstructive pulmonary Engrami  vol. 37  januar-mart 2015.  br. 1 disease, according to many studies, but it correlates poorly with measurements of life quality and the results reported by the depressed patients [10] [11] [12] . The stable chronic obstructive pulmonary disease prevalence of depression ranges between 10-42 % [12] [13] [14] [15] [16] [17] . The risk of depression is higher in patients with a more severe clinical picture of chronic obstructive pulmonary disease compared to the healthy population (15 %), with the highest percentage (62 %) found in patients with long-term oxygen therapy (DOT) [17] . In some studies, it is estimated that depression in chronic obstructive pulmonary disease occurs in the range from 6 % to 59 % [20] . The systematic analysis of 64 studies involving patients with severe clinical picture of chronic obstructive pulmonary disease showed that the prevalence of depression varied between 37-71 % in chronic obstructive pulmonary disease and was even higher than the prevalence of depression in patients with cancer, AIDS, heart disease and kidney disease [14] [15] [16] [17] [18] [19] [20] [21] [22] . In our research, conducted in primary health care in 2014, as an instrument of assessment of depression a screening questionnaire was used, created by the experts of the Ministry of Health of the Republic of Serbia. 835 patients were analyzed and fortified the prevalence of depressive symptoms higher than 9 % in patients with more severe clinical picture of chronic obstructive pulmonary disease.
The mechanism of the development of depression in chronic obstructive pulmonary disease is multifactorial [17] . Nowadays there are more and more studies proving that systemic inflammation leads to the appearance of depression symptoms. Interleukin-6 (IL-6) plays a particularly important role because it is increased in sputum, exhaled air and plasma of patients with chronic obstructive pulmonary disease, particularly during exacerbations. The concentration of IL-6 in plasma is correlated with increased Creactive protein (CRP) levels, being a major stimulator of CRP release from the liver. Since IL-6 is stable in the circulation, in contrast to other cytokines, it is considered to be involved in some of the systemic effects of chronic obstructive pulmonary disease. IL-6 is claimed to particularly contribute to the damage in endothelial cells functions, insulin resistance, osteoporosis and depression in patients with chronic obstructive pulmonary disease [19] .
The symptoms of chronic obstructive pulmonary diseases such as dyspnea, inactivity and consequential condition loss are claimed to cause even greater inactivity, social isolation, anxiety and symptoms of depression. Such patients often feel useless, are dependent on others in terms of care and worry and lose interest in future events [23] .
Several studies on development of depression in chronic obstructive pulmonary disease patients were conducted. The study by Polski and associates in 2005 that lasted ten years was one of the largest studies. 8387 adult patients were included and the emergence of depression symptoms after the diagnosis of one of the seven most common chronic diseases, including chronic obstructive pulmonary disease, was investigated. The control check-ups were performed every two years. Two years after the diagnosis of chronic obstructive pulmonary disease it was observed that the "hazard ratio" for the development of depression was 2.21, 3.55 for cancer and 1.45 for heart disease [25] . Patients with chronic ob-Engrami  vol. 37  januar-mart 2015.  br. 1 structive pulmonary disease have a variety of symptoms, ranging from shortterm depression symptoms and clinically manifested depression. Several studies claimed that two thirds of patients with chronic obstructive pulmonary disease had a moderate to severe depression [27] [28] [29] [30] . The study by Johannes and associates in 2003 reported that about one-quarter of patients with chronic obstructive pulmonary disease had an unrecognized depression.
Assessment of depression in chronic obstructive pulmonary disease
No diagnostic screening tool for the assessment of depression in patients with chronic obstructive pulmonary disease has been developed, so far, so the most commonly used instruments for depression symptoms assessment are the Beck Depression Inventory (BDI Beck Depression inventors) and Hamilton Depression (HRSD-Hamilton depression scale) [31] .
According to the GOLD guidelines, a detailed medical history of each newly detected patient with chronic obstructive pulmonary disease is recommended to be taken,, including the assessment of depression symptoms [32] [33] .
The recommendations from the United States (United States Preventive Task Force) state that all patients over 18 years of age should be screened for the presence of depression symptoms in primary care offices. All chronic patients and patients with chronic obstructive pulmonary disease should be included [33] .
CONCLUSION
Treatment of depression in patients with chronic obstructive pulmonary disease is multidisciplinary. The available medical treatment focuses on depression allievation symptoms, maintaining the basic functioning and improving the quality of life which would enable clinicians to recognize the disease deteriorations.
Patients suffering from chronic obstructive lung diseases are among the most accessible populations suitable for preventive work: they are a high-risk population and in constant contact with health professionals that can facilitate diagnosis and timely treatment of depression symptoms.
Bearing in mind the predictions of the World Health Organization, that by 2020 depression will have become the leading cause of mortality in the world and since it is now one of the medical conditions greatly affecting the deterioration of quality of life, adequate prevention is an imperative. 
Engrami
Sažetak
Prognoza bolesnika sa hroničnom opstruktivnom bolešću pluća je i dalje neizvesna, pogotovo kada je osnovno oboljenje komplikovano simptomima depresije čije lečenje prestavlja vrlo složen terapijski problem. Simptomi depresije javljaju se veoma često kod pacijenata koji boluju od hronične opstruktivne bolesti pluća, a utvrđena prevalenca u različitim studijama kreće se od 16% do 74%. Varijabilnost u studijama potiče od faze bolesti u kojoj se pacijenti nalazili u trenutku opservacije, metodama procene kao i različitim dijagnostičkim kriterijumima za hroničnu opstruktivnu bolest pluća i depresiju. Hronična opstruktivna bolest pluća udružena sa brojnim komorbiditetima, među kojima je i depresija, zauzima značajno mesto jer dovodi do češćeg korišćenja zdravstvenih usluga, češćih hospitalizacija, lošim fizičim i socijalnim funkcionisanjem. Bolesnici koji pate od hronične opstruktivne bolesti pluća spadaju u veoma dostupnu populaciju pogodnu za preventivni rad, pre svega zato što su visoko rizična populacija, a zatim i zbog toga što su u stalnom kontaktu sa zdravstvenim radnicima što olakšava dijagnostikovanje i blagovremeno lečenje simptoma depresije.
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